Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(1R,5R,7R)-3-benzyl-7-(piperidin-1-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one | 74% inhibition at 0.02 mM | Candida albicans | |
(1R,5R,7R)-3-benzyl-N-(2-hydroxyethyl)-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide | 71% inhibition at 0.02 mM | Candida albicans | |
(1R,5R,7R)-3-benzyl-N-(3-hydroxypropyl)-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide | 23% inhibition at 0.02 mM | Candida albicans | |
(1R,5R,7R)-3-benzyl-N-[(1R)-2-hydroxy-1-phenylethyl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide | 31% inhibition at 0.02 mM | Candida albicans | |
(1R,5R,7R)-3-benzyl-N-[(2R)-1-hydroxy-3-phenylpropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide | 29% inhibition at 0.02 mM | Candida albicans | |
(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide | 30% inhibition at 0.02 mM | Candida albicans | |
(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxy-4-methylpentan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide | 71% inhibition at 0.02 mM | Candida albicans | |
(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxypropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide | 35% inhibition at 0.02 mM | Candida albicans | |
(1R,5R,7R)-N-(2-aminoethyl)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide | 63% inhibition at 0.02 mM | Candida albicans | |
(1R,5S,7R)-3-benzyl-7-(1,4-diazepan-1-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one | 63% inhibition at 0.02 mM | Candida albicans | |
(1R,5S,7R)-3-benzyl-7-(morpholin-4-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one | 62% inhibition at 0.02 mM | Candida albicans | |
(1R,5S,7R)-3-benzyl-7-(thiomorpholin-4-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one | 58% inhibition at 0.02 mM | Candida albicans | |
(1R,5S,7R)-3-benzyl-7-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one | 34% inhibition at 0.02 mM | Candida albicans | |
(1R,5S,7R)-3-benzyl-7-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one | 48% inhibition at 0.02 mM | Candida albicans | |
(1R,5S,7R)-3-benzyl-7-[[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one | 58% inhibition at 0.02 mM | Candida albicans | |
(1R,5S,7S)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(R)-methylbutyl]amide | 60% inhibition at 0.02 mM | Candida albicans | |
(1R,5S,7S)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(S)-methylbutyl]amide | 33% inhibition at 0.02 mM | Candida albicans | |
(1S,5R,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid benzyl-(1-hydroxymethyl-3-methylbutyl)amide | 35% inhibition at 0.02 mM | Candida albicans | |
(1S,5R,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(R)-methylbutyl]amide | 29% inhibition at 0.02 mM | Candida albicans | |
(1S,5S,7S)-3-benzyl-7-(piperidine-1-carbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one | 50% inhibition at 0.02 mM | Candida albicans | |
ethyl 4-[[(1R,5S,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]oct-7-yl]carbonyl]piperazine-1-carboxylate | 74% inhibition at 0.02 mM | Candida albicans | |
fluconazole | - |
Candida albicans | |
pepstatin A | - |
Candida albicans |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Candida albicans | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
Bovine serum albumin + H2O | - |
Candida albicans | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
SAP2 | - |
Candida albicans |
secreted aspartic proteinase-2 | - |
Candida albicans |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.02 | - |
in 50 mM sodium citrate, pH 3.2, at 37°C | Candida albicans | (1S,5S,7S)-3-benzyl-7-(piperidine-1-carbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one |